bioAffinity Technologies (BIAF) Common Equity (2021 - 2026)

bioAffinity Technologies (BIAF) has 6 years of Common Equity data on file, last reported at $3.7 million in Q1 2026.

• Common Equity for Q1 2026 came in at $3.7 million, up 154.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.7 million (up 154.37% YoY), and the FY2025 annual result was $7.3 million, up 179.69% from the prior year.
• Common Equity slipped to $3.7 million in Q1 2026 per BIAF's latest filing, from $7.3 million in the prior quarter.
• Over five years, Common Equity peaked at $12.6 million in Q3 2022 and troughed at -$16.8 million in Q2 2022.
• A 5-year average of $3.1 million and a median of $4.9 million in 2023 frame the typical range for Common Equity.
• On a YoY basis, Common Equity climbed as much as 185.23% in 2025 and fell as far as 162.22% in 2025.
• A 5-year view of Common Equity shows it stood at $11.0 million in 2022, then plunged by 56.03% to $4.9 million in 2023, then plunged by 46.41% to $2.6 million in 2024, then soared by 179.69% to $7.3 million in 2025, then tumbled by 49.69% to $3.7 million in 2026.
• Business Quant data shows BIAF's Common Equity at $3.7 million in Q1 2026, $7.3 million in Q4 2025, and $8.9 million in Q3 2025.